https://scholars.lib.ntu.edu.tw/handle/123456789/108182
Title: | PHASE I STUDY OF BIWEEKLY GEMCITABINE FOLLOWED BY OXALIPLATIN AND SIMPLIFIED 48-H INFUSION OF FLUOROURACIL/LEUCOVORIN FOR ADVANCED PANCREATIC CANCER | Authors: | CHANG, HUI-JU WANG, CHUAN-CHENG CHENG, ANN-LII 張俊彥 |
Issue Date: | 2006 | Journal Volume: | v.21 | Journal Issue: | n.5 | Start page/Pages: | 874-879 | Source: | J GASTROENTEROL HEPATOL | Abstract: | Objectives: To evaluate the feasibility and maximal tolerated dose (MTD) of oxaliplatin of a triplet regimen consisting of gemcitabine, oxaliplatin and infusional fluorouracil (5-FU)/leucovorin (LV) (GOFL) for advanced pancreatic cancer. Patients and Methods: Patients with histologically proven metastatic or unresectable, locally advanced pancreatic adenocarcinoma were eligible to take part in the study. The treatment consisted of fixed-rate infusion (10 mg/m(2)/minute) of 800 mg/m(2) gemcitabine followed by 2-h infusion of oxaliplatin and then 48-h infusion of 5-FU/LV day 1 and day 15 every 4 weeks. The oxaliplatin would be evaluated at three dose levels, 65, 75 and 85 mg/m(2). Results: A total of 15 patients were enrolled at three dose levels. Dose-limiting toxicity of neutropenic fever and grade 4 thrombocytopenia occurred in one of each six patients at oxaliplatin dose level of 65 mg/ m(2) and 85 mg/m(2), respectively. The MTD of oxaliplatin for this combination was 85 mg/m(2). After a median four cycles of treatment, grade 3/4 neutropenia occurred in 46.7% of patients and thrombocytopenia in 13.3%. Non- hematological toxicities were generally of grade 1/2. Objective tumor response was observed in five patients (33.3 %, 95% confidence interval, 6.3-60.4%). Conclusion: Biweekly GOFL is a feasible regimen for advanced pancreatic cancer. For further phase II studies, the recommended dose of oxaliplatin is 85 mg/m(2). |
URI: | http://ntur.lib.ntu.edu.tw//handle/246246/80940 |
Appears in Collections: | 公共衛生學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.